🇺🇸 Almonertinib in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Asthenia — 1 report (10%)
2. Autoimmune Myositis — 1 report (10%)
3. Blood Potassium Abnormal — 1 report (10%)
4. Body Temperature Increased — 1 report (10%)
5. Constipation — 1 report (10%)
6. Decreased Appetite — 1 report (10%)
7. Drug-Induced Liver Injury — 1 report (10%)
8. Eye Swelling — 1 report (10%)
9. Eyelid Oedema — 1 report (10%)
10. Haemoglobin Decreased — 1 report (10%)

Source database →

Frequently asked questions

Is Almonertinib approved in United States?

Almonertinib does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Almonertinib in United States?

First People's Hospital of Hangzhou is the originator. The local marketing authorisation holder may differ — check the official source linked above.